Research & Literature

[The Hypereosinophilic Syndromes in Childhood].

Leu T, Simon HU, Hebestreit H, Kunzmann S

Klinische Padiatrie 2015; (227(6-7)):308-13 doi:10.1055/s-0035-1555792.

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

Helbig G, Soja A, Świderska A, et al.

Leukemia & lymphoma 2016; (57(3)):708-10 doi:10.3109/10428194.2015.1065983.

Hypereosinophilic Syndrome.

Curtis C, Ogbogu P

Clinical reviews in allergy & immunology 2016; (50(2)):240-51 doi:10.1007/s12016-015-8506-7.

Hypereosinophilic syndrome: cardiac diagnosis and management.

Mankad R, Bonnichsen C, Mankad S

Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.

Wang J, Zhang Q, Zeng H, et al.

Pharmacogenomics 2016; (17(2)):99-102 doi:10.2217/pgs.15.159.

Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.

Walker S, Wang C, Walradt T, et al.

Blood 2016; (127(7)):948-51 doi:10.1182/blood-2015-06-654277.

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.

Khoury P, Desmond R, Pabon A, et al.

Allergy 2016; (71(6)):803-10 doi:10.1111/all.12843.

The significance of early screening with echocardiography in eosinophilic granulomatosis with polyangiitis.

Tsugu T, Nagatomo Y, Yamada Y, et al.

Journal of medical ultrasonics (2001) 2016; (43(4)):527-31 doi:10.1007/s10396-016-0728-7.

Hydroxyurea-Mediated Cytotoxicity Without Inhibition of Ribonucleotide Reductase.

Liew LP, Lim ZY, Cohen M, et al.

Cell reports 2016; (17(6)):1657-1670 doi:10.1016/j.celrep.2016.10.024.

Hypereosinophilic syndrome.

Noh HR, Magpantay GG

Allergy and asthma proceedings 2017; (38(1)):78-81 doi:10.2500/aap.2017.38.3995.

Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism.

Yang QF, Lu TT, Shu CM, et al.

Experimental and therapeutic medicine 2017; (14(4)):3198-3206 doi:10.3892/etm.2017.4876.

[Pediatric idiopathic hypereosinophilic syndrome with pulmonary embolism: a case report and review of literature].

Dong N, Dong XY

Zhonghua er ke za zhi = Chinese journal of pediatrics 2017; (55(10)):775-779 doi:10.3760/cma.j.issn.0578-1310.2017.10.013.

Eosinophilic Myocarditis.

Cheung CC, Constantine M, Ahmadi A, et al.

The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.

Imatinib for the treatment of hypereosinophilic syndromes.

Helbig G

Expert review of clinical immunology 2018; (14(2)):163-170 doi:10.1080/1744666X.2018.1425142.

Loeffler endocarditis as a rare cause of heart failure with preserved ejection fraction: A case report and review of literature.

Gao M, Zhang W, Zhao W, et al.

Medicine 2018; (97(11)):e0079 doi:10.1097/MD.0000000000010079.

Acute Lymphoblastic Leukemia with Hypereosinophilia in a Child: Case Report and Literature Review.

Ferruzzi V, Santi E, Gurdo G, et al.

International journal of environmental research and public health 2018; (15(6)) doi:10.3390/ijerph15061169.

A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience.

Fang H, Ketterling RP, Hanson CA, et al.

American journal of clinical pathology 2018; (150(5)):421-431 doi:10.1093/ajcp/aqy064.

Idiopathic hypereosinophilic syndrome with pulmonary hypertension.

Zhang L, Peng X, Adhikari BK, et al.

Pulmonary circulation 2019; (9(1)):2045894018793999 doi:10.1177/2045894018793999.

Usefulness of Cardiac Magnetic Resonance in the Diagnosis of Löffler Endocarditis Secondary to Eosinophilic Granulomatosis with Polyangiitis.

Kurokawa K, Sai E, Hayashi E, et al.

Internal medicine (Tokyo, Japan) 2019; (58(2)):239-242 doi:10.2169/internalmedicine.1303-18.

Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome.

Li D, Xu L, Lin D, et al.

Respiratory medicine case reports 2018; (25()):213-215 doi:10.1016/j.rmcr.2018.09.006.

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.

Klion A

Hematology. American Society of Hematology. Education Program 2018; (2018(1)):326-331 doi:10.1182/asheducation-2018.1.326.

Hematological dyspnea: A rare cause with gratifying recovery.

Gupta A, Ananthakrishna R, Rao DPV, et al.

Journal of cardiology cases 2015; (12(3)):83-86 doi:10.1016/j.jccase.2015.05.010.

When Hypereosinophilia Leads to Stroke.

Chalayer E, Pelissier A, Tardy B

European journal of case reports in internal medicine 2017; (4(6)):000614 doi:10.12890/2017_000614.

A case report of Löffler endocarditis in idiopathic hypereosinophilic syndrome: recovery is possible.

Abayazeed RM, Abdel-Hay MA, Elfwal S, Hssanein M

European heart journal. Case reports 2018; (2(2)):yty030 doi:10.1093/ehjcr/yty030.

Teaching NeuroImages: Multifocal cerebral infarcts as a presentation of idiopathic hypereosinophilic syndrome.

Wasilewski A

Neurology 2019; (92(18)):e2178 doi:10.1212/WNL.0000000000007407.

Long-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome.

Awadie H, Khoury J, Zohar Y, et al.

Rambam Maimonides medical journal 2019; (10(3)) doi:10.5041/RMMJ.10373.

Hypereosinophilic dermatitis: generalised lichenification and gyrate erythema as the sole manifestation of idiopathic hypereosinophilic syndrome.

Yadav D, Sharma A, Agarwal S, Gupta V

BMJ case reports 2019; (12(10)) doi:10.1136/bcr-2019-232142.

Rare manifestation of hypereosinophilic syndrome: Diffuse-type hair loss with massive perifollicular eosinophils.

Suzuki H, Fukui R, Tabata N, Aiba S

The Journal of dermatology 2020; (47(1)):61-63 doi:10.1111/1346-8138.15139.

Cough in hypereosinophilic syndrome: case report and literature review.

Xie J, Zhang J, Zhang X, et al.

BMC pulmonary medicine 2020; (20(1)):90 doi:10.1186/s12890-020-1134-x.

Single-Organ and Multisystem Hypereosinophilic Syndrome Patients with Gastrointestinal Manifestations Share Common Characteristics.

Kuang FL, Curtin BF, Alao H, et al.

The journal of allergy and clinical immunology. In practice 2020; (8(8)):2718-2726.e2 doi:10.1016/j.jaip.2020.04.025.

Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome.

Schuster B, Zink A, Eyerich K

Allergy 2020; (75(11)):3003-3006 doi:10.1111/all.14368.

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.

Roufosse F, Kahn JE, Rothenberg ME, et al.

The Journal of allergy and clinical immunology 2020; (146(6)):1397-1405 doi:10.1016/j.jaci.2020.08.037.

Acute progressive stroke with middle cerebral artery occlusion caused by idiopathic hypereosinophilic syndrome: a case report.

Li QF, Zhang Q, Huang YF, Zhang ZX

BMC neurology 2020; (20(1)):361 doi:10.1186/s12883-020-01941-8.

Serum Levels of Eosinophil-derived Neurotoxin in Patients with Chronic Urticaria.

Saleh AA, Al-Obaidi AM, Behiry EG, Hamed AM

The Journal of clinical and aesthetic dermatology 2020; (13(9)):21-23.

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab.

Requena G, Roufosse F, Baylis LD, Steinfeld J

Respirology case reports 2021; (9(2)):e00707 doi:10.1002/rcr2.707.

Favorable Response to Interferon-α in Infantile-onset Idiopathic Hypereosinophilic Syndrome Complicated by Status Epilepticus During Treatment.

Kanchongkittiphon W, Kittinon K, Wanitchakorn A, et al.

Journal of pediatric hematology/oncology 2021; (43(7)):e1052-e1053 doi:10.1097/MPH.0000000000002052.

Hypereosinophilic syndrome with multiorgan involvement: an interdisciplinary work-up.

Looman KIM, Nuver ME, Korevaar TIM, Guillen SS

BMJ case reports 2021; (14(2)) doi:10.1136/bcr-2020-240243.

A case of hypereosinophilic syndrome with STAT5b N642H mutation.

Ding F, Wu C, Li Y, et al.

Oxford medical case reports 2021; (2021(1)):omaa129 doi:10.1093/omcr/omaa129.

Idiopathic Hypereosinophilic Syndrome with Multiple Organ Involvement.

Abo Shdid R, Azrieh B, Alebbi S, et al.

Case reports in oncology 2021; (14(1)):249-255 doi:10.1159/000511396.

Leg ulcer with long-term hydroxyurea use.

Ammad Ud Din M, Hussain SA, Jamshed S

Clinical case reports 2021; (9(4)):2487-2488 doi:10.1002/ccr3.3991.

Hypereosinophilic syndrome: considerations for the cardiologist.

Bondue A, Carpentier C, Roufosse F

Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.

The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom.

Requena G, Logie J, Gibbons DC, et al.

Immunity, inflammation and disease 2021; (9(4)):1447-1451 doi:10.1002/iid3.495.

FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.

Tennenbaum J, Groh M, Venditti L, et al.

Stroke 2021; (52(10)):e605-e609 doi:10.1161/STROKEAHA.121.034191.

Clinical analysis of hypereosinophilic syndrome first presenting with asthma-like symptoms.

Wei X, Li X, Wei Z, et al.

Annals of medicine 2022; (54(1)):11-21 doi:10.1080/07853890.2021.2014555.

Loeffler endocarditis with intracardiac thrombus: case report and literature review.

Zhang Q, Si D, Zhang Z, Zhang W

BMC cardiovascular disorders 2021; (21(1)):615 doi:10.1186/s12872-021-02443-2.

Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.

Requena G, van den Bosch J, Akuthota P, et al.

The journal of allergy and clinical immunology. In practice 2022; (10(8)):2125-2134 doi:10.1016/j.jaip.2022.03.034.

Hypereosinophilic syndrome presenting as acute ischemic stroke, myocardial infarction, and arterial involvement: A case report.

Sun RR, Chen TZ, Meng M

World journal of clinical cases 2022; (10(11)):3547-3552 doi:10.12998/wjcc.v10.i11.3547.

Case Report: An Unusual Presentation of Cardiovascular Involvement in Eosinophilic Granulomatosis With Polyangiitis.

Li Y, Zhou H, Zhou Y, Tang H

Frontiers in cardiovascular medicine 2022; (9()):928192 doi:10.3389/fcvm.2022.928192.

Updates on eosinophilic disorders.

Tzankov A, Reichard KK, Hasserjian RP, et al.

Virchows Archiv : an international journal of pathology 2023; (482(1)):85-97 doi:10.1007/s00428-022-03402-8.

Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: The Mayo Clinic Experience.

Zayas J, Peters MS, Butterfield JH, et al.

Journal of cutaneous pathology 2023; (50(5)):455-465 doi:10.1111/cup.14410.

JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome.

Faguer S, Groh M, Vergez F, et al.

Clinical immunology (Orlando, Fla.) 2023; (251()):109275 doi:10.1016/j.clim.2023.109275.

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.

Shomali W, Colucci P, George TI, et al.

Leukemia 2023; (37(5)):981-987 doi:10.1038/s41375-023-01859-3.

Hyepereosiniphilic syndrome and COVID-19: 2 case reports.

Sherafati A, Rahmanian M, Sattarzadeh Badkoubeh R, et al.

Journal of cardiothoracic surgery 2023; (18(1)):158 doi:10.1186/s13019-023-02241-1.

The international consensus classification of eosinophilic disorders and systemic mastocytosis.

Wang SA, Orazi A, Gotlib J, et al.

American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

Idiopathic Hypereosinophilic Syndrome: A Case Report.

Agudo M, Santos F, Teixeira Reis A, et al.

Cureus 2023; (15(6)):e39964 doi:10.7759/cureus.39964.

Chronic Oro-Genital Ulcerations as a Presenting Feature of Chronic Eosinophilic Leukemia: A Case Report.

Padhiyar J, Patel N, Lakum M, Shah H

Indian dermatology online journal 2023; (14(4)):524-526 doi:10.4103/idoj.idoj_477_22.

Idiopathic Hypereosinophilic Syndrome Presenting with Recalcitrant Oral and Genital Ulcers Responding Well to Thalidomide.

Srinivas SM, Chebbi PG, Shivappa SK

Indian dermatology online journal 2023; (14(5)):676-678 doi:10.4103/idoj.idoj_632_22.

An 85-Year-Old Man with Fever, Dyspnea, and Dry Cough Diagnosed with Idiopathic Hypereosinophilic Syndrome, Successfully Treated with High-Dose Corticosteroids.

Goyal P, Chhabra ST, Tandon R, et al.

The American journal of case reports 2023; (24()):e941241 doi:10.12659/AJCR.941241.

Hypereosinophilic syndrome associated with multiple thromboses requiring ICU admission: A case report.

Ouanes I, Toumi S, Ben Cheikh Y, et al.

La Tunisie medicale 2023; (101(10)):783-786.

Eosinophilia and wheeze: thinking beyond asthma.

Kuek SL, Pettman C, Neeland MR, et al.

Breathe (Sheffield, England) 2024; (20(1)):230126 doi:10.1183/20734735.0126-2023.

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

Shomali W, Gotlib J

American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.

Groh M, Fenwarth L, Labro M, et al.

American journal of hematology 2024; (99(6)):1108-1118 doi:10.1002/ajh.27306.

Hypereosinophilic syndrome: a rare cause of ST-elevation myocardial infarction and thrombus formation on the aortic valve.

Jørgensen MD, Schneider IR, Thomsen GN, Dahl JS

BMJ case reports 2024; (17(4)) doi:10.1136/bcr-2023-259494.

When Blood Cell Counts Matter: Hypereosinophilic Syndrome as a Rare Cause of Ischemic Strokes.

Kaur G, Rodriguez W, Ganev Y, et al.

Cureus 2024; (16(5)):e60557 doi:10.7759/cureus.60557.

Hydration of N-Hydroxyurea from Ab Initio Molecular Dynamics Simulations.

Balicki M, Śmiechowski M

Molecules (Basel, Switzerland) 2024; (29(11)) doi:10.3390/molecules29112435.

Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program.

Coussement G, Catherine J, Roufosse F

Journal of leukocyte biology 2024; (116(5)):1021-1032 doi:10.1093/jleuko/qiae152.

Multiple Cerebral Infarcts and Encephalopathy as the First Clinical Manifestations of Hypereosinophilic Syndrome: A Case Report and Narrative Review.

Romano S, Avola G, Angeli MC, et al.

Pulse (Basel, Switzerland) 2024; (12(1)):106-112 doi:10.1159/000539379.

[Hypereosinophilic syndrome, case report and diagnostic approach].

Medina-Marroquín R, Espejel-Guzman JA, Maldonado-López CJ, Calzada-Rascón AC

Revista medica del Instituto Mexicano del Seguro Social 2024; (62(2)):1-6.

Cardiac Abnormalities in Hypereosinophilic Syndromes.

Hotta VT, Nastari RR, Oishi GDSL, et al.

Arquivos brasileiros de cardiologia 2024; (121(10)):e20240190 doi:10.36660/abc.20240190.

Myocarditis with neurological and dermatological involvement in idiopathic Hypereosinophilic syndrome: Case report.

Ihssane M, Asmae M, Nisrine A, et al.

Radiology case reports 2025; (20(3)):1666-1670 doi:10.1016/j.radcr.2024.11.091.

Clinical Management of Persistent Hypereosinophilia.

Helbig G, Czachor K

European journal of haematology 2025; (114(5)):763-774 doi:10.1111/ejh.14396.

Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study.

Mattioli I, Urban ML, Padoan R, et al.

Journal of autoimmunity 2025; (153()):103398 doi:10.1016/j.jaut.2025.103398.

Eosinophilia and gastrointestinal symptoms in Immunosuppression: a classic but overlooked diagnosis.

Lopes S, Carvalho A, Gamito É, Alves AL

Revista espanola de enfermedades digestivas 2025; doi:10.17235/reed.2025.11284/2025.

Non-invasive biomarkers to diagnose and monitor eosinophilic esophagitis: a systematic review.

Noble SL, Tyrrell R, Mules TC, Inns S

Frontiers in medicine 2025; (12()):1607306 doi:10.3389/fmed.2025.1607306.

Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis.

Merkel PA, Nair PK, Khalidi N, et al.

Annals of the rheumatic diseases 2025; (84(11)):1888-1899 doi:10.1016/j.ard.2025.06.2131.

Non-atherosclerotic myocardial infarction in hypereosinophilic syndrome: emerging insights and therapeutic approaches.

Li J, Jia W, Li Q, et al.

Heart (British Cardiac Society) 2025; doi:10.1136/heartjnl-2025-326273.

Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study.

Talmon A, Shamriz O, Rubin L, et al.

Frontiers in immunology 2025; (16()):1702989 doi:10.3389/fimmu.2025.1702989.

Real-world outcomes after anti-IL-5/anti-IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review.

Jain P, Rowell J, Edmonds C, et al.

The journal of allergy and clinical immunology. Global 2026; (5(1)):100608 doi:10.1016/j.jacig.2025.100608.

Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?

Nanzer AM, Terrier B, Wechsler ME

The journal of allergy and clinical immunology. In practice 2026; (14(3)):613-618 doi:10.1016/j.jaip.2026.01.014.